Patent intelligence · US
US 12123012
Methods and compositions for nucleic acid and protein payload delivery
Methods and compositions for nucleic acid and protein payload delivery
Patent details — US 12123012
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 22, 2024
- Expiration
- Oct 17, 2044
- Applicant
- LIGANDAL, INC.
- Claims
- 5
- CPC classes
- A61K, A61K31/40, A61K31/7105, A61K47/34
Quick answer
US 12123012 (Methods and compositions for nucleic acid and protein payload delivery) is held by LIGANDAL, INC.. Status: granted. Granted Oct 22, 2024. Expires Oct 17, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LIGANDAL, INC.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/40, A61K31/7105, A61K47/34, A61K47/42, A61K47/549
More from LIGANDAL, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12403087
Topical antiviral compositions, delivery systems, and methods of using the same
granted -
US 12319651
Crystalline forms and methods of producing crystalline forms of a compound
granted -
US 12246014
Azetidine derivatives
granted -
US 12208071
Glucagon receptor antagonists
granted -
US 11970482
Acetal compounds and therapeutic uses thereof
granted -
US 11952364
TRK inhibitors useful as anticancer drugs
granted -
US 11773110
Heterocycle amines and uses thereof
granted
Frequently asked questions
What is US patent 12123012?
US 12123012 (Methods and compositions for nucleic acid and protein payload delivery) is held by LIGANDAL, INC.. Status: granted. Granted Oct 22, 2024. Expires Oct 17, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12123012?
LIGANDAL, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 133 pharmaceutical patents for this assignee.
When does US 12123012 expire?
Our index shows an expiration date of Oct 17, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.